BioCentury
ARTICLE | Clinical News

Oncopeptides' melflufen shows similar efficacy to new MM therapies

June 16, 2015 2:10 AM UTC

Data presented at the European Hematology Association meeting showed that melflufen from Oncopeptides AB (Stockholm, Sweden) could have similar efficacy to other clinical candidates in heavily pre-treated multiple myeloma patients.

In the Phase II portion of a Phase I/II study, melflufen plus dexamethasone led to an objective response rate of 52% among 21 evaluable patients with relapsed/refractory MM. Median progression-free survival was 7.6 months among 25 patients, including four who progressed rapidly and were not considered evaluable for efficacy. Melflufen is a prodrug of melphalan. ...